Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome
Details
Serval ID
serval:BIB_57012024DD2E
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome
Journal
Clinical Cardiology
ISSN
0160-9289 (Print)
Publication state
Published
Issued date
06/1985
Volume
8
Number
6
Pages
321-6
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Jun
Research Support, Non-U.S. Gov't --- Old month value: Jun
Abstract
Flecainide is reported to be effective in patients with paroxysmal tachycardias, but its effect on rapid ventricular response over accessory atrioventricular pathway during atrial fibrillation is not known. The influence of flecainide on various electrophysiological properties of the accessory pathway with special emphasis on ventricular rate during atrial fibrillation was investigated in 9 patients with severe symptomatic Wolff-Parkinson-White syndrome. The shortest ventricular response during atrial fibrillation increased from 218 (190-270) to 320 (240-block) ms. In 4 patients sustained rapid atrial fibrillation converted to sinus rhythm. The rate of circus movement tachycardia decreased from 166/min to 130/min after flecainide, due to a lengthening of retrograde ventriculoatrial conduction time over the accessory pathway. Flecainide caused a significant prolongation of the effective refractory period of the accessory pathway in our subgroup with extremely fast AV conduction during atrial fibrillation and induced a depressant effect on retrograde accessory pathway conduction. This makes the drug very promising for the emergency treatment of dangerous rapid tachyarrhythias complicating this syndrome.
Keywords
Adolescent
Adult
Anti-Arrhythmia Agents/*therapeutic use
Atrial Fibrillation/*drug therapy
Cardiac Pacing, Artificial
Electrocardiography
Female
Flecainide
Heart Rate/drug effects
Humans
Infusions, Parenteral
Male
Middle Aged
Piperidines/*therapeutic use
Wolff-Parkinson-White Syndrome/*drug therapy
Pubmed
Web of science
Create date
15/02/2008 11:28
Last modification date
20/08/2019 14:11